

CITATION REPORT

List of articles citing

Diversity of mechanism-based pharmacodynamic models

DOI: 10.1124/dmd.31.5.510

Drug Metabolism and Disposition, 2003, 31, 510-8.

Source: <https://exaly.com/paper-pdf/35812404/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
305	Feedback linearization using neural networks applied to advanced pharmacodynamic and pharmacogenomic systems.		5
304	In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR). 2003 , 4, 791-9		22
303	. 2004 ,		8
302	Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis Volume 3. 2004 ,		1
301	Pharmacodynamics and Pharmacogenomics of Corticosteroids: Microarray Studies. 2004 , 85-103		1
300	Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. 2004 , 311, 830-5		24
299	Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding. 2004 , 21, 231-6		13
298	Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. 2004 , 75, 60-9		6
297	Mechanism-Based PK/PD Modeling of Digoxin: Role of Receptor Heterogeneity and Postreceptor Events. 2004 , 67-83		
296	Pharmacokinetics and Pharmacodynamics of Biotech Drugs. 2005 , 145-172		2
295	A dynamical systems analysis of the indirect response model with special emphasis on time to peak response. 2005 , 32, 607-54		18
294	Disease system analysis: basic disease progression models in degenerative disease. 2005 , 22, 1038-49		77
293	Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. 2005 , 22, 1432-7		146
292	Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. 2005 , 22, 1589-96		168
291	A dynamic neuro-fuzzy model providing bio-state estimation and prognosis prediction for wearable intelligent assistants. 2005 , 2, 15		5
290	An event-driven neuro-fuzzy model for adaptive prognosis in homeostatic systems.		0
289	Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. 2005 , 11, 8856-65		56

288	Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells. 2005 , 13, 199-212	22
287	Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. 2005 , 44, 61-98	510
286	Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. 2005 , 44, 331-47	104
285	Fuzzy Logic and Applications. 2006 ,	0
284	Exposure-Response Relationships for Therapeutic Biologic Products. 2006 , 295-327	12
283	Pharmacokinetics and Pharmacodynamics of Biotech Drugs. 2006 ,	1
282	Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. 2006 , 79, 461-79	317
281	An integrated model of thermodynamic-hemodynamic-pharmacokinetic system and its application on decoupling control of intracranial temperature and pressure in brain hypothermia treatment. 2006 , 242, 16-31	11
280	Quantitative structure-pharmacokinetic/pharmacodynamic relationships. 2006 , 58, 1326-56	68
279	Pharmacokinetic-pharmacodynamic modelling: history and perspectives. 2006 , 33, 227-79	132
278	Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. 2006 , 33, 635-55	10
277	Target-mediated drug disposition and dynamics. 2006 , 72, 1-10	192
276	Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. 2006 , 319, 1297-306	55
275	. 2006 ,	2
274	Pharmacokinetic-Pharmacodynamic Modeling and Simulation. 2006 ,	1
273	Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 1816-23	4 66
272	Pharmacogenomics and Pharmacokinetic/Pharmacodynamic Modeling. 509-528	1
271	Mechanistic Pharmacokinetic/Pharmacodynamic Models II. 607-631	2

270	Preclinical Pharmacokinetics. 253-278	1
269	Integrated pharmacokinetics and pharmacodynamics in drug development. 2007 , 46, 713-37	48
268	Challenges and opportunities with modelling and simulation in drug discovery and drug development. 2007 , 37, 1295-310	84
267	Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration-Effect Relationships [Application in Drug Candidate Selection and Lead Optimization. 2007 , 885-908	3
266	Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. 2007 , 63, 1-11	20
265	A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. 2007 , 81, 529-38	115
264	The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. 2007 , 12, 1018-24	119
263	Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. 2007 , 47, 357-400	203
262	PKPD model of interleukin-21 effects on thermoregulation in monkeys--application and evaluation of stochastic differential equations. 2007 , 24, 298-309	13
261	Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys. 2007 , 34, 559-74	1
260	Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. 2007 , 34, 727-51	87
259	Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. 2008 , 35, 349-77	26
258	Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. 2008 , 377, 637-45	25
257	Development of translational pharmacokinetic-pharmacodynamic models. 2008 , 83, 909-12	95
256	The Hill equation: a review of its capabilities in pharmacological modelling. 2008 , 22, 633-48	479
255	Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. 2008 , 47, 417-48	71
254	Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. 2008 , 29, 186-91	222
253	Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 1267-74	4 89

252	Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. 2008 , 7, 407-17	43
251	Pharmacokinetic/pharmacodynamic modeling of cardiac toxicity in human acute overdoses: utility and limitations. 2008 , 4, 569-79	7
250	Modern Drug Discovery and Development. 2009 , 361-380	2
249	In silico simulation of corticosteroids effect on an NFkB- dependent physicochemical model of systemic inflammation. 2009 , 4, e4706	55
248	Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults. 2009 , 49, 916-28	19
247	Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans. 2009 , 330, 169-78	22
246	Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and A	43
245	Combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration. 2009 , 98, 1885-904	26
244	Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. 2009 , 36, 63-80	19
243	Modeling of tumor growth and anticancer effects of combination therapy. 2009 , 36, 179-97	83
242	A model-based approach to the in vitro evaluation of anticancer activity. 2009 , 63, 827-36	20
241	The time course of drug effects. 2009 , 8, 176-85	14
240	Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework. 2010 , 106, 2-12	16
239	Exploring the role of the immune response in preventing antibiotic resistance. 2009 , 256, 655-62	55
238	Monotonicity of the peak time in turnover models. 2009 , 347, 495-500	1
237	Modeling endotoxin-induced systemic inflammation using an indirect response approach. 2009 , 217, 27-42	75
236	Pharmacokinetics and pharmacodynamics of antimicrobial drugs. 2009 , 5, 475-87	23
235	Rational Design of Oral Modified-Release Drug Delivery Systems. 2009 , 469-499	3

234	Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. 2009 , 24, 16-24	94
233	Modeling and Simulation in Clinical Drug Development. 2010 , 1	
232	Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. 2010 , 12, 1-10	46
231	Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. 2010 , 12, 592-601	30
230	Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. 2010 , 12, 729-40	58
229	Prediction of exposure-response relationships to support first-in-human study design. 2010 , 12, 750-8	34
228	Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. 2010 , 161, 488-508	203
227	Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. 2010 , 24, 1619-29	51
226	Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 1436-42	4 68
225	Multiscale model for the assessment of autonomic dysfunction in human endotoxemia. 2010 , 42, 5-19	42
224	A systematic review and empirical analysis of the relation between dose and duration of drug action. 2010 , 50, 17-26	6
223	A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. 2010 , 10, 446-55	353
222	Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling. 2010 , 6, 1063-81	48
221	Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor. 2010 , 40, 751-62	20
220	Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against <i>Pseudomonas aeruginosa</i> . 2010 , 54, 2379-84	19
219	Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. 2010 , 5, 927-41	66
218	Blood concentrations are better predictors of chloroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships. 2010 , 48, 904-15	24
217	Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)acetamide, a novel MET kinase inhibitor. 2011 , 41, 327-39	9

216	Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process. 2011 , 41, 1076-87	6
215	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling During Discovery and Early Development. 2011 , 175-199	
214	Simultaneous Pharmacokinetic/Pharmacodynamic Modeling. 2011 , 255-294	0
213	A Model-Based PK/PD Antimicrobial Chemotherapy Drug Development Platform to Simultaneously Combat Infectious Diseases and Drug Resistance. 2011 , 251-279	3
212	Using neural networks to determine the contribution of danshensu to its multiple cardiovascular activities in acute myocardial infarction rats. 2011 , 138, 126-34	16
211	What it takes to understand and cure a living system: computational systems biology and a systems biology-driven pharmacokinetics-pharmacodynamics platform. 2011 , 1, 16-23	8
210	The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. 2011 , 13, 111-20	43
209	Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation. 2011 , 38, 369-83	10
208	Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. 2011 , 67, 349-60	41
207	Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. 2011 , 68, 1413-9	34
206	Theoretical analysis of time-to-peak responses in biological reaction networks. 2011 , 73, 978-1003	4
205	Pharmacokinetics. 2011 , 3, 332-342	3
204	Bioanalytical considerations in the comparability assessment of biotherapeutics. 2011 , 3, 613-22	9
203	Anti-arthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. 2011 , 338, 154-63	75
202	Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model. 2011 , 55, 1571-9	33
201	Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. 2011 , 336, 881-90	31
200	Clinical Trial Simulations. 2011 ,	12
199	Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. 2011 , 17, 4682-92	85

198	Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. 2012 , 341, 617-25	15
197	Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. 2012 , 72, 1632-41	28
196	Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. 2012 , 18, 3090-9	65
195	Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 919-27	4 29
194	ADME of biologics-what have we learned from small molecules?. 2012 , 14, 410-9	41
193	Use of pharmacokinetic data below lower limit of quantitation values. 2012 , 29, 2628-31	19
192	Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. 2012 , 52, 1624-44	27
191	Drug Stereochemistry. 2012 ,	46
190	Physiologically-Based Pharmacokinetics of Biotherapeutics. 2012 , 209-259	1
189	Integration of PBPK and Pharmacodynamics. 2012 , 299-382	
188	An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. 2012 , 52, 629-44	58
187	Development of Antibody-Based Therapeutics. 2012 ,	5
186	Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma. 2012 , 30, 413-29	17
185	Computational Toxicology. 2012 ,	9
184	Integrating experimentation and quantitative modeling to enhance discovery of Beta amyloid lowering therapeutics for Alzheimer's disease. 2012 , 3, 177	5
183	Pharmacokinetic/pharmacodynamic modeling in inflammation. 2012 , 40, 295-312	21
182	Biomarkers and Therapeutic Drug Monitoring in Psychiatry. 2012 ,	1
181	Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. 2012 , 18, 3846-55	97

180	Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. 2012 , 385, 337-72	60
179	The Hill equation and the origin of quantitative pharmacology. 2012 , 66, 427-438	166
178	Lifespan based indirect response models. 2012 , 39, 109-23	14
177	Novel Biopharmaceuticals. 2013 , 97-137	4
176	Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. 2013 , 15, 354-66	40
175	Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. 2013 , 4, 1504	153
174	Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. 2013 , 71, 1147-57	27
173	Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. 2013 , 52, 1063-83	14
172	A model for educational simulation of the effect of oxytocin on uterine contractions. 2013 , 35, 524-31	3
171	Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. 2013 , 65, 1053-90	192
170	Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. 2013 , 139, 61-9	28
169	Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. 2013 , 72, 1255-64	15
168	Stochastic modeling of systems mapping in pharmacogenomics. 2013 , 65, 912-7	6
167	A multiscale modeling approach to inflammation: A case study in human endotoxemia. 2013 , 244, 279-289	6
166	A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans. 2013 , 28, 1830-6	10
165	The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models. 2013 , 7, 95	50
164	Pharmacokinetic and pharmacodynamic modeling of drug absorption and delivery. 2013 , 24-38	
163	Translation of central nervous system occupancy from animal models: application of pharmacokinetic/pharmacodynamic modeling. 2013 , 347, 2-6	17

162	Nonautonomous Dynamical Systems in the Life Sciences. 2013 ,	9
161	Differential analysis of transient increases of serum cTnI in response to handling in rats. 2013 , 1, e00011	2
160	Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ^9 -tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. 2013 , 76, 65-77	23
159	Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 2104-13	37
158	Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative. 2014 , 10, 929-52	36
157	Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models. 2014 , 5, 232	11
156	Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. 2014 , 5, 174	103
155	Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes. 2014 , 41, 127-39	6
154	Quantifying pharmacodynamic interaction between atenolol and valsartan. 2014 , 9, 1-9	0
153	Subcellular drug targeting, pharmacokinetics and bioavailability. 2014 , 22, 95-115	12
152	Pharmacokinetics. 2014 , 87, 93-120	162
151	Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure. 2014 , 239, 1225-39	103
150	Highly multiplexed and reproducible ion-current-based strategy for large-scale quantitative proteomics and the application to protein expression dynamics induced by methylprednisolone in 60 rats. 2014 , 86, 8149-57	32
149	Role of Modeling and Simulation in Toxicology Prediction. 2014 , 53-72	
148	Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. 2014 , 41, 291-318	22
147	Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development. 2014 , 70, 73-85	24
146	Dynamic Models of Disease Progression: Toward a Multiscale Model of Systemic Inflammation in Humans. 2014 , 319-368	
145	Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations. 2015 , 4, e00016	57

144	Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab. 2015 , 41, 132-41	7
143	PKPD modelling to predict altered disposition of 1 α ,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation. 2015 , 172, 3611-26	5
142	PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. 2015 , 112, 3493-8	169
141	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. 2015 , 28, 70-81	301
140	Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. 2015 , 6, 33	10
139	Translating slow-binding inhibition kinetics into cellular and in vivo effects. 2015 , 11, 416-23	94
138	Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps. 2015 , 11, 743-56	15
137	Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis. 2015 , 42, 611-26	1
136	Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells. 2015 , 354, 448-58	21
135	Visual Predictive Check in Models with Time-Varying Input Function. 2015 , 17, 1455-63	2
134	Distributed transit compartments for arbitrary lifespan distributions in aging populations. 2015 , 380, 550-8	2
133	Pharmacologic considerations in use and development of antituberculosis drugs. 2014 , 5, a021170	0
132	International Pharmaceutical Product Registration. 2016 ,	1
131	Pharmaceutical Biotechnology. 2016 ,	5
130	Mechanistic Models of Physiological Control Systems. 2016 , 137-158	
129	Irreversible Pharmacodynamics. 2016 , 211-227	
128	Foundations of Pharmacodynamic Systems Analysis. 2016 , 161-175	2
127	Direct, Indirect, and Signal Transduction Response Modeling. 2016 , 177-209	1

126 Classical Pharmacodynamics. **2016**, 343-360

125 Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics. **2016**, 17

124 Time-Dependent Effects in Algae for Chemicals with Different Adverse Outcome Pathways: A Novel Approach. **2016**, 50, 7770-80 7

123 Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. **2016**, 6, 492-503 3

122 Translating Molecular Biomarkers into Clinical Assays. **2016**,

121 Advancing In Vitro-In Vivo Extrapolations of Mechanism-Specific Toxicity Data Through Toxicokinetic Modeling. **2017**, 157, 293-317 2

120 Assessment of non-linear combination effect terms for drug-drug interactions. **2016**, 43, 461-79 14

119 In silico toxicology: computational methods for the prediction of chemical toxicity. **2016**, 6, 147-172 310

118 An adaptive and generalizable closed-loop system for control of medically induced coma and other states of anesthesia. **2016**, 13, 066019 24

117 Biophysical and Biochemical Analysis of Recombinant Proteins. **2016**, 39-64 7

116 Modelling Drug Abuse Epidemics in the Presence of Limited Rehabilitation Capacity. **2016**, 78, 2364-2389 8

115 Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. **2016**, 12, 253-65 8

114 Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1 β 25-Dihydroxyvitamin D3 in Mice. *Drug Metabolism and Disposition*, **2016**, 44, 189-208 4 11

113 Mechanism-based pharmacokinetic-pharmacodynamic modeling of salvianolic acid A effects on plasma xanthine oxidase activity and uric acid levels in acute myocardial infarction rats. **2017**, 47, 208-216 7

112 Unsupervised learning of pharmacokinetic responses. **2017**, 32, 409-428 1

111 Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats. **2017**, 390, 457-470 1

110 In vitro Environmental Toxicology - Concepts, Application and Assessment. **2017**, 2

109 Translational pharmacology and HIV reservoir eradication strategies. **2017**, 12, 631-633

108	Modern Drug Discovery and Development. 2017 , 719-743	4
107	Quantitative systems toxicology. 2017 , 4, 79-87	22
106	Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014). 2017 , 6, 418-429	38
105	Dermal Drug Selection and Development. 2017 ,	4
104	Integrated TK-TD modeling for drug-induced concurrent tachycardia and QT changes in beagle dogs. 2017 , 44, 449-462	2
103	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice. 2017 , 362, 441-449	5
102	Exponential Decay Metrics of Topical Tetracaine Hydrochloride Administration Describe Corneal Anesthesia Properties Mechanistically. 2017 , 36, 363-366	2
101	Understanding and applying pharmacometric modelling and simulation in clinical practice and research. 2017 , 83, 247-254	53
100	Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. 2017 , 9, 15-28	7
99	A pumpless multi-organ-on-a-chip (MOC) combined with a pharmacokinetic-pharmacodynamic (PK-PD) model. 2017 , 114, 432-443	78
98	Understanding Physiology in the Continuum: Integration of Information from Multiple - Levels. 2017 , 8, 91	11
97	Rational Design of Oral Modified-Release Drug Delivery Systems. 2017 , 519-554	5
96	BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism. 2017 , 7, 17935	8
95	Human PK Prediction and Modeling. 2017 , 51-82	
94	Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics. 2018 , 13, 539-550	7
93	Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips. 2018 , 58, 37-64	103
92	Model selection for clustering of pharmacokinetic responses. 2018 , 162, 11-18	1
91	Highlighting Vitamin D Receptor-Targeted Activities of 1,25-Dihydroxyvitamin D in Mice via Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 75-87	4 11

90	Experimental Studies and Modeling of the Drying Kinetics of Multicomponent Polymer Films. 2018 , 19, 425-435	19
89	Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systems. 2018 , 20, 102	7
88	Stimulus-Response Mechanisms: An Overview. 2018 , 161-170	
87	PK/PD Approaches. 2018 , 1-23	1
86	Predictive Systems Toxicology. 2018 , 1800, 535-557	3
85	Hybrid multiparametric model predictive control with application to the neuromuscular blockade. 2018 ,	
84	Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib. 2018 , 433-466	1
83	Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect. 2018 , 7, 660-669	6
82	Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. 2018 , 6, e00402	10
81	Variable Order Fractional Derivatives and Bone Remodeling in the Presence of Metastases. 2018 , 1-36	
80	GR Dimerization and the Impact of GR Dimerization on GR Protein Stability and Half-Life. 2019 , 10, 1693	12
79	A study on discrete and discrete fractional pharmacokinetics-pharmacodynamics models for tumor growth and anti-cancer effects. 2019 , 7, 10-24	22
78	Cytokine Therapeutics in Cancer Immunotherapy: Design and Development. 2019 , 5, 377-390	2
77	A Three-dimensional and Dynamic (3DD) Cell Culture System for Evaluation of Pharmacokinetics, Safety and Efficacy of Anti-cancer Drugs. 2019 , 5, 460-467	1
76	Pharmacological Assessment of Sepiapterin Reductase Inhibition on Tactile Response in the Rat. 2019 , 371, 476-486	4
75	PK/PD Approaches. 2019 , 1-23	2
74	Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics. 2019 , 50, 120-127	12
73	Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations. 2019 , 31, 69-80	38

72	Causa Nostra: The Potentially Legitimate Business of Drawing Causal Inferences From Observational Data. 2019 , 8, 253-255	1
71	Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins. 2019 , 105-137	3
70	Development of a non-human primate model to support CNS translational research: Demonstration with D-amphetamine exposure and dopamine response. 2019 , 317, 71-81	
69	Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients. 2019 , 108, 732-740	1
68	Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review. 2019 , 71, 699-723	10
67	Pharmacokinetic and pharmacodynamic insights from microfluidic intestine-on-a-chip models. 2019 , 15, 1005-1019	24
66	Ordinary differential equation approximation of gamma distributed delay model. 2019 , 46, 53-63	3
65	Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses. 2020 , 109, 1169-1177	0
64	Multi-scale modeling of drug binding kinetics to predict drug efficacy. 2020 , 77, 381-394	12
63	An Integrated TK-TD Model for Evaluation of Radix Aconitikusnezoffii (RAK). 2020 , 105, 669-680	
62	Model organism development and evaluation for late-onset Alzheimer's disease: MODEL-AD. 2020 , 6, e12110	21
61	Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Development. 2020 , 149-176	
60	Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. 2020 , 11, 997	16
59	Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids. 2020 , 72, 414-438	13
58	Entering the era of computationally driven drug development. 2020 , 52, 283-298	10
57	The guard changes. 2020 , 47, 3-4	
56	Pharmacokinetic/Pharmacodynamic Modeling To Predict the Antiplatelet Effect of the Ticagrelor-Loaded Self-Microemulsifying Drug Delivery System in Rats. 2020 , 17, 1079-1089	1
55	A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib. 2021 , 39, 100362	1

54	Kinetics of Drug-Target Binding: A Guide for Drug Discovery. 2021 ,	0
53	Square root law model for the delivery and intestinal absorption of drugs: a case of hydrophilic captopril. 2021 , 28, 1685-1694	0
52	Model-informed drug development and discovery: an overview of current practices. 2021 , 263-280	0
51	OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control. 2021 , 189, 46-65	2
50	A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine Synergism. 2021 , 377, 305-315	1
49	Introduction: Utility of Mathematical Models in Drug Development and Delivery. 2021 , 1-41	
48	Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models. 2021 , 88, 867-878	1
47	Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma. 2021 , 23, 101	0
46	Dynamic modeling of bone remodeling, osteolytic metastasis and PK/PD therapy: introducing variable order derivatives as a simplification technique. 2021 , 83, 39	0
45	Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. 2021 , 39, 1404-1421.e11	6
44	Heart/liver-on-a-chip as a model for the evaluation of cardiotoxicity induced by chemotherapies. 2021 , 3, 100008	4
43	Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics of Protein Therapeutics. 1	1
42	Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Development. 1	2
41	Genetic Programming and Neural Networks Feedback Linearization for Modeling and Controlling Complex Pharmacogenomic Systems. 2006 , 178-187	3
40	Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics. 2013 , 101-132	8
39	Mechanism-based pharmacodynamic modeling. 2012 , 929, 583-600	61
38	Mathematical Concepts in Pharmacokinetics and Pharmacodynamics with Application to Tumor Growth. 2013 , 225-250	6
37	PK Principles and PK/PD Applications. 2009 , 59-98	2

- 36 An agent-based model of cellular dynamics and circadian variability in human endotoxemia. **2013**, 8, e55550 13
- 35 Pharmacokinetics and Pharmacodynamics Models of Tumor Growth and Anticancer Effects in Discrete Time. **2020**, 8, 114-125 7
- 34 PBPK MODELING OF BIOTHERAPEUTICS. **2021**, 225-262
- 33 MODELING PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTERACTIONS. **2021**, 65-128
- 32 Preclinical Pharmacokinetics. 1
- 31 Nonlinear Mixed Effects Models: Case Studies. **2011**, 359-390
- 30 Dynamic Models of Disease Progression: Toward a Multiscale Model of Systemic Inflammation in Humans. 319-368
- 29 Multiscale Integration of Toxicokinetic and Toxicodynamic Processes: From Cell and Tissue to Organ and "Whole Body" Models.
- 28 Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics. **2012**, 285-302 0
- 27 Toxicokinetics and Drug Disposition. **2013**, 55-76
- 26 Pharmacometrics of Hyperlipidemia. **2014**, 539-562
- 25 CHAPTER 18: Pharmacokinetic/Pharmacodynamic Modeling in Drug Development with Special Reference to Oncology. **2015**, 391-413
- 24 ADME for Therapeutic Biologics: What Can We Leverage from Great Wealth of ADME Knowledge and Research for Small Molecules. 1-11
- 23 Application of Quantitative Biomeasures in Early Drug Discovery. **2016**, 37-46
- 22 New Advancements in Exposure-Response Analysis to Inform Regulatory Decision Making. **2016**, 303-317 0
- 21 Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors. **2016**, 121-150
- 20 Topical Drug Candidate Selection Criteria and Cascade. **2017**, 115-131 1
- 19 Pharmacodynamic Evaluation: Infectious Diseases. **2018**, 1-18

- 18 The ADME Encyclopedia. **2021**, 1-13
- 17 Chapter 4: Integrated Translation Framework for Endocrine Disruptors in the area of Computational Toxicology. **2020**, 80-120 1
- 16 PK/PD Approaches. **2020**, 1047-1069
- 15 Pharmacodynamic Evaluation: Infectious Diseases. **2020**, 325-342
- 14 Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development. **2007**, 27, 1237-46
- 13 Mathematical Modeling for an MTT Assay in Fluorine-Containing Graphene Quantum Dots.. **2022**, 12, 0
- 12 Optimization of Propofol Dose Estimated During Anesthesia Through Artificial Intelligence by Genetic Algorithm: Design and Clinical Assessment. 1
- 11 A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114.. **2021**, 0
- 10 Kinetics of Drug Action: A PKPD Approach. **2022**, 601-613
- 9 Growth-rate model predicts in vivo tumor response from in vitro data. 0
- 8 Optimal Timing of Intravenous Acetaminophen Administration for Postoperative Analgesia. **2022**, 69, 3-10
- 7 Towards a comprehensive assessment of QSP models: what would it take?. 1
- 6 Evaluation of the Key Advantages between Two Modalities of Boronophenylalanine Administration for Clinical Boron Neutron Capture Therapy Using an Animal Model. **2022**, 11, 2736 0
- 5 General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimisation of study protocols for small molecules and monoclonal antibodies in children. 0
- 4 An Artificial Intelligence Framework for Optimal Drug Design. 0
- 3 Teaching computational systems biology with an eye on quantitative systems pharmacology at the undergraduate level: Why do it, who would take it, and what should we teach?. 2, 0
- 2 The Impact of Trap-Assisted Tunneling and Poole-Frenkel Emission on Synaptic Potentiation in an $\text{Fe}_2\text{O}_3/\text{p-Si}$ Memristive Device. **2023**, 5, 3 0
- 1 Machine learning for pharmacokinetic/pharmacodynamic modeling. **2023**, 0

